These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21821981)

  • 21. Migration of human dendritic cells after injection in patients with metastatic malignancies.
    Morse MA; Coleman RE; Akabani G; Niehaus N; Coleman D; Lyerly HK
    Cancer Res; 1999 Jan; 59(1):56-8. PubMed ID: 9892184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells.
    Breckpot K; Heirman C; Neyns B; Thielemans K
    J Gene Med; 2004 Nov; 6(11):1175-88. PubMed ID: 15468193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced cancers].
    Kato Y
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2240-2. PubMed ID: 21224534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma.
    Coosemans A; Wölfl M; Berneman ZN; Van Tendeloo V; Vergote I; Amant F; Van Gool SW
    Anticancer Res; 2010 Sep; 30(9):3709-14. PubMed ID: 20944158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring immune therapy for renal cancer.
    Matsushita H; Kakimi K; Tomita Y; Tatsugami K; Naito S; Suekane S; Noguchi M; Moriya F; Matsuoka K; Itoh K; Kobayashi H; Eto M; Takahashi W; Kawano Y; Wada Y
    Int J Urol; 2011 Jun; 18(6):412-21. PubMed ID: 21599759
    [No Abstract]   [Full Text] [Related]  

  • 26. Dendritic cells: limited potential in immunotherapy.
    Soruri A; Zwirner J
    Int J Biochem Cell Biol; 2005 Feb; 37(2):241-5. PubMed ID: 15474968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Yasukawa M; Fujiwara H; Ochi T; Suemori K; Narumi H; Azuma T; Kuzushima K
    Am J Hematol; 2009 May; 84(5):314-5. PubMed ID: 19338044
    [No Abstract]   [Full Text] [Related]  

  • 28. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy.
    Yannelli JR; Wroblewski JM
    Vaccine; 2004 Nov; 23(1):97-113. PubMed ID: 15519713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical applications of dendritic cell vaccines.
    Morse MA; Lyerly HK
    Curr Opin Mol Ther; 2000 Feb; 2(1):20-8. PubMed ID: 11249649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generation of dendritic cell-based vaccines for cancer therapy.
    Reinhard G; Märten A; Kiske SM; Feil F; Bieber T; Schmidt-Wolf IG
    Br J Cancer; 2002 May; 86(10):1529-33. PubMed ID: 12085199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic cells in cancer immunotherapy.
    Vulink A; Radford KJ; Melief C; Hart DN
    Adv Cancer Res; 2008; 99():363-407. PubMed ID: 18037410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunology in medical practice. XXV. Use of dendritic cells in the immunotherapy of cancer].
    Punt CJ; de Vries IJ; Mulders PF; Adema GJ; Figdor CG
    Ned Tijdschr Geneeskd; 1999 Nov; 143(48):2408-14. PubMed ID: 10608974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy with dendritic cells for cancer.
    Ballestrero A; Boy D; Moran E; Cirmena G; Brossart P; Nencioni A
    Adv Drug Deliv Rev; 2008 Jan; 60(2):173-83. PubMed ID: 17977615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The novel bispecific diabody alphaCD40/alphaCD28 strengthens leukaemic dendritic cell-induced T-cell reactivity.
    Houtenbos I; Santegoets S; Westers TM; Waisfisz Q; Kipriyanov S; Denkers F; Scheper RJ; de Gruijl TD; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2008 Jun; 142(2):273-83. PubMed ID: 18492117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cells as therapeutic vaccines against cancer.
    Banchereau J; Palucka AK
    Nat Rev Immunol; 2005 Apr; 5(4):296-306. PubMed ID: 15803149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personalized cancer vaccines.
    Jain KK
    Expert Opin Biol Ther; 2010 Dec; 10(12):1637-47. PubMed ID: 20979567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia.
    Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
    Haematologica; 2006 Mar; 91(3):348-55. PubMed ID: 16531258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease.
    Tsuboi A; Oka Y; Kyo T; Katayama Y; Elisseeva OA; Kawakami M; Nishida S; Morimoto S; Murao A; Nakajima H; Hosen N; Oji Y; Sugiyama H
    Leukemia; 2012 Jun; 26(6):1410-3. PubMed ID: 22157809
    [No Abstract]   [Full Text] [Related]  

  • 39. Global sensitivity analysis and model-based reactive scheduling of targeted cancer immunotherapy.
    Kiran KL; Lakshminarayanan S
    Biosystems; 2010 Aug; 101(2):117-26. PubMed ID: 20639123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cell vaccines for leukemia patients.
    Schmitt A; Hus I; Schmitt M
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):275-83. PubMed ID: 17338648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.